Get started
BAYERBAYERBAYER

BAYER

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals Bonds

4BAYN trade ideas

BAYER BULLISH ON COVID-19 TREATMENT President Donald Trump and the Food and Drug Administration commissioner appeared to exchange conflicting statements about how a decades-old antimalaria drug is being used to treat COVID-19. The drug in question is chloroquine. It is sold under the brand name Aralen and in generic form. It is also available in a different formulation as hydroxychloroquine under the brand name Plaquenil. In both its chloroquine and hydroxychloroquine formulations, it is approved as a treatment for rheumatoid arthritis. At a news conference on Thursday, Trump said the drug had been approved as a treatment for COVID-19 and that it had “gone through the approval process.” He later said the FDA is “continuing to study the drug.” FDA commissioner Stephen Hahn said that while chloroquine has been approved for other indications, it would still need to go through clinical trials. “That’s a drug that the president has directed us to take a closer look at as to whether an expanded use approach to that could be done to actually see if that benefits patients,” Hahn said. The term “expanded access,” which is interchangeably used with compassionate use, is a FDA regulatory pathway for people to use investigational treatments if there are no other approved options available in some life-threatening circumstances. There are currently no FDA-approved treatments or vaccines for the novel coronavirus, which was first detected in December in Wuhan, China. The virus has since sickened more than 234,000 people worldwide, including at least 10,000 people in the U.S., and killed at least 9,700 people. A number of companies have announced that they plan to or are already conducting clinical trials to evaluate investigational or FDA-approved drugs as potential treatments for COVID-19. Gilead Sciences Inc.’s GILD, -1.09% remdesivir, for example, hasn’t been approved for any indication in the U.S. However, at least three clinical trials are under way to evaluate the safety and efficacy of the drug in the treatment of people with COVID-19, including one in partnership with the National Institutes of Health. Regeneron Pharmaceuticals Inc. REGN, +0.99%, Sanofi SNY, -2.49% and Roche Holding ROG, -1.769% have said this week that they plan to conduct clinical trials testing their rheumatoid arthritis drugs as potential treatments. Regeneron and Sanofi’s Kevzara was first approved by the FDA in 2017, while Roche’s Actemra received FDA approval in 2010. In Hahn’s comments on Thursday, he talked about the need to consider already approved drugs as potential treatments because they have a proven safety profile, unlike those that haven’t yet been evaluated in clinical trials. Those therapies may serve as a “bridge” during the pandemic, he said. Bayer AG BAYRY, +0.97% on Thursday afternoon announced that it had donated three million tablets of Resochin, a chloroquine product. The German drugmaker said that it is seeking an emergency use authorization for the drug in the U.S., where it is not approved. Mylan MYL, +4.86% also said Thursday that it had restarted production of hydroxychloroquine-sulfate tablets. A kind of early-days review of available medical reports argues that “there is sufficient preclinical rationale and evidence regarding the effectiveness of chloroquine for treatment of COVID-19,” according to a corrected proof published this month in the Journal of Critical Care by researchers in Israel and Italy. A corrected proof is not a peer-reviewed medical study, which is considered the gold standard of medical research. However, given the speed at which the coronavirus outbreak in China’s Hubei Province has turned into a global pandemic, there has not enough time so far for research to go through the peer-review process. SOURCE MARKETWATCH
OTC:BAYRY
by OTCMarketsExpert
Bayer AG in up trend after breakout - how to tradeMarket broke out of triangle at the end of July and confirmed the current up trend after closing above down trend channel at the beginning of August. We have seen two bullish indicators on daily chart. 1. 50 day moving average (yellow line) crossed the 100 day moving average (blue line) upwards which is bullish indicator, expect fast up movement above 70 € if the yellow 50 day moving average (red line) should cross the red 200 day moving average line upwards within next days 2. Price on daily chart closed above the down trend line which is bullish indicator as well but market need to break another down trend channel line before turning bullish finally. How to trade: - if you hold already long positions: wait for clear sell signal at 70 € resistance. should market not break above the trend line within 3-4 days than sell otherwise hold until drawn long term take profit area which will be reached 100 % after breakout from last resistance channel - if you want to open a long position: wait for a correction movement to 200 day moving average at 62 € which is first strong support. Several daily candle close above it implement further up movement -don´t short this stock currently because the risk is higher than the reward chance, remember that the all time high was at 144 € which is more than 50 % away from current price area. Fundamental view: Bayer is still a healthy company which will win most of the open us court processes, after that we can expect again prices above 100 € Yesterday the Bayer AG selled its pharmaceuticals business for pets and livestock. It goes for 7. 6 billion dollars (6. 85 billion euros) to the US company Elanco, as the Leverkusen DAX company announced on Tuesday. The sale marks a step forward in Bayer's intention to sell businesses and reduce debt following the expensive acquisition of the seed company Monsanto. There has already been speculation about such a deal. Of this sum, 5. 3 billion dollars are to be paid in cash, Bayer reported. The remaining 2. 3 billion is paid in shares by Elanco. The Leverkusen-based company intends to sell its stake in Elanco in due course. The transaction volume corresponds to 18. 8 times the underlying earnings before interest, taxes, depreciation and amortization (EBITDA) of the Bayer Animal Health business in the twelve months to June. The deal is expected to close in mid-2020, subject to the approval of competition authorities. Elanco, once part of US pharma giant Eli Lilly, is an industry leader with 5600 employees and $3. 1 billion in sales. The Bayer deal was said to create the global number two in animal health. The US group Zoetis is the market leader. Bayer sells flea, tick and deworming products as well as collars to ward off vermin in veterinary medicine. The Group offers farmers means to strengthen the defences of farm animals, combat pests in the stables and improve hygiene. Bayer had described the outlook for the division as good. But veterinary medicine is also Bayer's smallest division, with its subsidiary based in Monheim and production facilities in Kiel and Shawnee (USA) employing around 3,700 people, or a good three percent of Bayer's workforce. Measured in terms of revenue of 1. 6 billion euros, the division is also negligible: Bayer had sales of almost 40 billion in 2018.
XETR:BAYNLong
by DK_Investment
BAYER found its way back to its long term uptrend channelChart Analysis Let's have a look at MIL:BAY , the famous Monsanto buyer. Last weeks candle managed to close inside the long term uptrend channel and if we look at the monthly chart we can see a strong green confirmation candle forming. Of course we have still 5 trading days for this month, but maybe it works out. then it confir ms the reversal which happened at the 78.6 / 86 Fibonacci area. risky... but there is a chance Of course there a many risks and uncertainness in Bayer regarding the Glyphosate, but the company is looking for a roundup settlement in trails. For the marked this is good news, because Bayer accepts that they have to pay and don't fight against it. So if they can negotiate this settlement the market has a clear number and there is an end of trails visible and possible. Nothing is more difficult for a stock than (bad) unclarity. Dividend 4.2% Dividend 46 % Payout Ratio Monthly Chart
MIL:1BAYNLong
by MH77
Bayer will accompany us for a whileFor some time now, I have been monitoring Bayer AG. We have seen a huge disintegration since 2015 which now meets crucial levels of support. The MACD will soon show a cross on a monthly basis at a crucial level. Let's take a look at the Fibu we see the Bayer currently commuting at the 78er. that means the entire bull market from the year 2012 -2015 was given back and this at the same pace as he has also increased. I will soon be trading a knockout certificate with the Bayer title on the long side. Also I put a few shares in the depot which can rest for a few years. We still have some time left before we can / should invest
XETR:BAYNLong
by logindaten
Is Bayer Going To Need Aspirin For Their Roundup Issues?Bayer is a descending Triangle Chart Pattern Strong support level has been re-tested several times Continually lower highs puts pressure on this support level Best patterns have dropping volume and volatility/ATR Fewer traders are interested in this consolidatation At some point expect an explosive breakout Trade Plan Wait for a close below the support level Full trade size if volume is at average atr line 1/2 trade size as long as bar has 75% of average volume Enter two trade Both trades SL is 1.5xATR 1st trade TP is 1xATR 2nd trade no TP let profit run When price hits 1st TP move 2nd trade AL to breakeven Let profit run If breakout candle is more than 1 ATR wait for price to retrace back towards 1 ATR level to enter
MIL:1BAYNShort
by Tradingstrategyguides